---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116370"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:56:54.569205+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Quoin reports positive Phase 2 data for QRX003 in Netherton Syndrome; cash $14M

## Summary
- Five of six evaluable subjects showed negligible/absent pruritus after QRX003 treatment in open-label study.
- All six subjects improved in Investigator skin scoring; favorable patient global assessment across metrics.
- No safety concerns in either ongoing study; protocol amendments planned: eliminate lower 2% dose, twice-daily dosing.
- Cash, equivalents and marketable securities $14.0M as of Sept 30, 2023; runway expected through end of 2024.
- Net loss $2.1M for Q3 2023 vs $2.3M for Q3 2022; nine-month net loss $7.2M flat year-over-year.

## SEC filing metadata
- accession: 0001104659-23-116370
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/0001104659-23-116370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/tm2330370d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116370
- JSON: https://secwatch.observer/filing/0001104659-23-116370.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116370.txt

## Key facts
- Earnings Releases
  Quoin Pharmaceuticals, Ltd. reported the quarter ended September 30, 2023 results: net income approximately $2.1 million.
  - Period: the quarter ended September 30, 2023
  - Net income: approximately $2.1 million
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023 was approximately $2.1 million compared to approximately $2.3 million for the quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671502/000110465923116370/0001104659-23-116370-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.